Skip to main content
SpringerLink
Log in

Molekulares Profil im Visier

Personalisierte Therapie bei Brustkrebs

  • fortbildung
  • Published:
Info Onkologie Aims and scope

Die personalisierte Medizin bei Patientinnen mit einem Mammakarzinom spielt eine immer größere Rolle im klinischen Alltag. Der Einsatz einer zielgerichteten Therapie bietet vielen Betroffenen die Chance auf eine wirksamere Behandlung mit weniger Nebenwirkungen und längerem Überleben.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Zitiert nach: Damm R: Personalisierte Medizin und Patientenrecht — Medizinische Optionen und medizinrechtliche Bewertung. Zeitschrift für Medizinrecht. 2011;29:7–17.

  2. Mehta R et al. Personalized medicine: the road ahead. Clin Breast Cancer. 2011;11(1):20–6.

    Article  PubMed  CAS  Google Scholar 

  3. Fisher B et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001;93(2):112–20.

    Article  PubMed  CAS  Google Scholar 

  4. Rosen PP et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol. 1989;7(9):1239–51.

    PubMed  CAS  Google Scholar 

  5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

    Google Scholar 

  6. Siegmund-Schultze N. Dtsch Arztebl. 2011;108(37): A-1904/B-1622/C-1609

    Google Scholar 

  7. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.

    Article  PubMed  CAS  Google Scholar 

  8. Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

    Article  PubMed  CAS  Google Scholar 

  9. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26(25):3637–43.

    Article  PubMed  CAS  Google Scholar 

  10. Capelan M et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–82.

    Article  PubMed  CAS  Google Scholar 

  11. Mengel M et al. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol. 2002;198(3):292–9.

    Article  PubMed  Google Scholar 

  12. Urruticoechea A et al. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212–20.

    Article  PubMed  CAS  Google Scholar 

  13. Varga Z et al. Efforts to standardise Ki-67 counting in breast cancer. Pathologe. 2011;32(Suppl 1):143(Abstr So-089).

    Google Scholar 

  14. S3-Leitlinien Mammakarzinom, 2012. www.awmf.org

  15. Schmidt M et al. Biomarkers in Breast Cancer-An Update, Geburtsh Frauenheilk. 2012;72(9):819–32.

    Article  CAS  Google Scholar 

  16. Harbeck N et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 2002;62(16):4617–22.

    PubMed  CAS  Google Scholar 

  17. Jänicke F et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93(12):913–20.

    Article  PubMed  Google Scholar 

  18. Simon RM et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446–52.

    Article  PubMed  Google Scholar 

  19. Albain KS et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.

    Article  PubMed  CAS  Google Scholar 

  20. Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.

    Article  PubMed  CAS  Google Scholar 

  21. Goldhirsch A et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.

    Article  PubMed  CAS  Google Scholar 

  22. Harris L et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.

    Article  PubMed  CAS  Google Scholar 

  23. NCCN. National Comprehensive Cancer Network. Breast cancer. V. 2.2011. 2011.

  24. Filipits M et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012–20.

    Article  PubMed  CAS  Google Scholar 

  25. Darby S et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.

    Article  PubMed  CAS  Google Scholar 

  26. Bartelink H et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259–65.

    Article  PubMed  Google Scholar 

  27. Vaidya JS et al. Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial -updated analysis of local recurrence and first analysis of survival. Cancer Res 2012;72(Suppl 24):Abstr S4–2.

    Google Scholar 

  28. Wenz F et al. Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-rays: the first 5 years of experience with a novel approach. Int J Radiat Oncol Biol Phys. 2010;77(5):1309–14.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum des Saarlandes, Homburg/Saar, Deutschland

    Gilda Schmidt, Jochen Fleckenstein &  Ingolf Juhasz-Böss

  2. Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Kirrbergerstr. 100, 66424, Homburg/Saar, Deutschland

    Ingolf Juhasz-Böss

Authors
  1. Gilda Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jochen Fleckenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ingolf Juhasz-Böss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ingolf Juhasz-Böss.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, G., Fleckenstein, J. & Juhasz-Böss, I. Molekulares Profil im Visier. Info Onkol. 16, 38–41 (2013). https://doi.org/10.1007/s15004-013-0639-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-013-0639-3

Search

Navigation